title: Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
abstract: OBJECTIVE
  To report the management of a rare case of ovarian hyperstimulation syndrome (OHSS) induced by tamoxifen therapy for breast cancer in a 50-year-old woman.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Gynecology outpatient department of a university hospital.
  
  
  METHODS
  A 50-year-old premenopausal patient with a history of breast cancer was prescribed adjuvant treatment with tamoxifen.
  
  
  METHODS
  Temporary discontinuation of tamoxifen therapy resolved symptoms, but resumption of tamoxifen caused a recurrence of symptoms. Surgical bilateral salpingo-oophrectomy was therefore performed.
  
  
  METHODS
  Resolution of symptoms of OHSS.
  
  
  RESULTS
  Bilateral salpingo-oophrectomy rendered the patient postmenopausal and enabled the commencement of the aromatase inhibitor anastrozole as an alternative adjuvant therapy for breast cancer.
  
  
  CONCLUSIONS
  Tamoxifen-induced OHSS is rare. Furthermore, OHSS is very rare in the older female. OHSS usually resolves with temporary discontinuation of tamoxifen, however, the recurrence of symptoms when resuming tamoxifen is better treated with bilateral salpingo-oophorectomy to enable adjuvant treatment with anastrazole.
authors.affiliation: University of Sheffield, Jessops Hospital, Sheffield, United Kingdom.
authors.forename: Amy
authors.initials: A
authors.lastname: Baigent
authors.forename: Hany
authors.initials: H
authors.lastname: Lashen
mesh_terms: D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D057915:Drug Substitution; D005260:Female; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D010052:Ovariectomy; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects*; D013629:Tamoxifen / Q000009:adverse effects*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole